What is the recommended treatment for a Candida parapsilosis urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Candida parapsilosis Urinary Tract Infection

For Candida parapsilosis UTI, oral fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks is the recommended first-line treatment due to its excellent urinary penetration and C. parapsilosis susceptibility profile. 1

Diagnostic Considerations

Before initiating treatment, it's important to distinguish between true infection and colonization:

  • Pyuria and colony counts are not reliable indicators of infection when catheters are present
  • Imaging (ultrasound or CT) is helpful to identify structural abnormalities, hydronephrosis, or fungus balls
  • Symptoms of cystitis or pyelonephritis support true infection versus asymptomatic colonization

Treatment Algorithm

First-line therapy:

  • Fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks 1
    • Fluconazole achieves high urinary concentrations
    • C. parapsilosis shows high susceptibility to fluconazole (93% efficacy) 2
    • Available in both oral and intravenous formulations

Alternative therapies (if fluconazole cannot be used):

  1. Amphotericin B deoxycholate 0.3-0.6 mg/kg/day IV for 1-7 days 1, 3

    • Effective but has toxicity concerns and requires IV administration
    • Monitor renal function closely
  2. Liposomal amphotericin B 3-5 mg/kg/day IV 1

    • For severe infections or fluconazole-resistant isolates
    • Less nephrotoxic than conventional amphotericin B

Adjunctive measures (critical for successful treatment):

  • Remove indwelling bladder catheter if present (strong recommendation) 1
  • Correct any urinary tract obstruction (strong recommendation) 1
  • Consider surgical intervention for fungus balls 1

Special Situations

Fluconazole-resistant C. parapsilosis:

  • Uncommon but possible scenario
  • Amphotericin B deoxycholate 0.3-0.6 mg/kg/day IV for 1-7 days 1
  • Consider amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) for cystitis 1

Severe infection or pyelonephritis:

  • Treat as candidemia with systemic therapy 1
  • Consider longer duration of therapy (>2 weeks)

Treatment Duration and Monitoring

  • Treat for 2 weeks after symptom resolution 1
  • Obtain follow-up urine cultures to document clearance
  • Monitor for clinical improvement of symptoms

Important Caveats

  • Echinocandins (caspofungin, micafungin, anidulafungin) have minimal urinary excretion and are generally ineffective for UTIs despite in vitro activity 1, 4
  • Lipid formulations of amphotericin B do not achieve adequate urine concentrations for UTI treatment 1
  • Voriconazole and other azoles (except fluconazole) have minimal urinary excretion and are not recommended 1, 4
  • C. parapsilosis infections may be more complicated than other Candida species and might require more aggressive treatment 5

By following this treatment approach focusing on fluconazole as first-line therapy and addressing any underlying factors like catheter removal or obstruction, most C. parapsilosis UTIs can be effectively treated with minimal complications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fluconazole treatment of candidal infections caused by non-albicans Candida species.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1996

Research

Candida urinary tract infections in adults.

World journal of urology, 2020

Research

Candida urinary tract infections--treatment.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.